InspireMD reported Q2 2026 revenue of $1.8 million, flat year-over-year, driven by a 21% international growth offset by U.S. sales declines due to a voluntary recall of the CGuard Prime 135 cm delivery system. The company incurred a net loss of $14.3 million ($0.17 per share), including $612,000 in inventory impairment and $734,000 in customer credits related to the recall. U.S. revenue turned negative at $(351,000). Following the quarter, InspireMD initiated cost-saving actions expected to yield approximately $9 million in annual savings. The company appointed Kathleen Kennedy as SVP of Global Sales and Marketing ahead of a planned U.S. re-launch. Clinical updates included 100% acute device success in the CGUARDIANS II trial for TCAR procedures and enrollment commencement in the CGUARDIANS III pivotal trial. InspireMD develops medical devices, specifically carotid stent systems, to prevent stroke.

InspireMD, Inc. announced on July 23, 2026, that it provided notice to Chief Commercial Officer Shane Gleason that his position has been eliminated, with his last day of employment set for July 31, 2026. This executive departure is a material event affecting the company's leadership structure. InspireMD, Inc. operates in the medical device industry, specializing in interventional cardiology products.

On July 17, 2026, InspireMD, Inc. received notice from Nasdaq that it is not in compliance with Listing Rule 5550(a)(2) because its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days ending July 16, 2026. The company has until January 13, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. The company is evaluating options to regain compliance, including a potential reverse stock split. InspireMD, Inc. operates in the medical device industry, developing and commercializing innovative technologies for the treatment of cardiovascular disease.

Raymond W. Cohen resigned from the board of directors, the Audit Committee, and the Compensation Committee of InspireMD, Inc. effective July 1, 2026. The resignation was for personal reasons and not due to any disagreement with the company's operations or management. The Nominating and Corporate Governance Committee is seeking a replacement. InspireMD, Inc. is a medical device company that develops and commercializes innovative technologies for the treatment of cardiovascular disease.

InspireMD, Inc. issued a press release on June 11, 2026, announcing 30-day results from the CGUARDIANS II clinical trial regarding the CGuard Prime 80 cm implant for use in TCAR procedures. InspireMD, Inc. is a medical device company specializing in neurovascular technologies.